Embecta (EMBC) Projected to Post Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) will likely be posting its Q1 2026 results before the market opens on Thursday, February 5th. Analysts expect Embecta to post earnings of $0.67 per share and revenue of $258.0660 million for the quarter. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, February 5, 2026 at 8:00 AM ET.

Embecta (NASDAQ:EMBC) last announced its earnings results on Tuesday, November 25th. The company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.04. The company had revenue of $263.30 million during the quarter, compared to analyst estimates of $265.66 million. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The firm’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.45 earnings per share. On average, analysts expect Embecta to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Embecta Stock Down 1.9%

EMBC opened at $10.20 on Thursday. The business’s fifty day simple moving average is $12.14 and its 200 day simple moving average is $12.94. Embecta has a 52 week low of $9.20 and a 52 week high of $19.00. The stock has a market cap of $603.94 million, a PE ratio of 6.26 and a beta of 1.11.

Embecta Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Friday, December 5th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.9%. The ex-dividend date of this dividend was Friday, December 5th. Embecta’s dividend payout ratio (DPR) is currently 36.81%.

Institutional Trading of Embecta

Institutional investors have recently modified their holdings of the company. Larson Financial Group LLC grew its stake in shares of Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after buying an additional 6,224 shares during the period. Wexford Capital LP bought a new stake in shares of Embecta in the 3rd quarter worth approximately $94,000. Humankind Investments LLC bought a new stake in shares of Embecta in the 2nd quarter worth approximately $111,000. Finally, iSAM Funds UK Ltd bought a new position in shares of Embecta during the third quarter valued at approximately $115,000. 93.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on EMBC shares. Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Zacks Research cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, BTIG Research reiterated a “buy” rating on shares of Embecta in a research report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $18.50.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.